-transparent.png){kind=logo}
This study assessed the ability of high doses of caffeine to reverse changes in alertness and mood produced by prolonged sleep deprivation. Fifty healthy, nonsmoking males between the ages of 18 and 32 served as volunteers. Following 49 h without sleep, caffeine (0, 150, 300, or 600 mg/70 kg, PO) was administered in a double-blind fashion. Measures of alertness were obtained with sleep onset tests, the Stanford Sleepiness Scale (SSS), and Visual Analog Scales (VAS). Sleep deprivation decreased onset to sleep from a rested average of 19.9 min to 7 min. Following the highest dose of caffeine tested, sleep onset averaged just over 10 min; sleep onset for the placebo group averaged 5 min. Scores on the SSS increased from a rested mean of 1.6-4.8 after sleep deprivation. Caffeine reduced this score to near rested values. Caffeine reversed sleep deprivation-induced changes in three subscales of the POMS (vigor, fatigue, and confusion) and produced values close to fully rested conditions on several VAS. Serum caffeine concentrations peaked 90 min after ingestion and remained elevated for 12 h. This study showed that caffeine was able to produce significant alerting and long-lasting beneficial mood effects in individuals deprived of sleep for 48 h.
D Penetar, and
U McCann, and
D Thorne, and
G Kamimori, and
C Galinski, and
H Sing, and
M Thomas, and
G Belenky
September 2005,
Journal of sleep research,
D Penetar, and
U McCann, and
D Thorne, and
G Kamimori, and
C Galinski, and
H Sing, and
M Thomas, and
G Belenky
January 2013,
Annals of thoracic medicine,
D Penetar, and
U McCann, and
D Thorne, and
G Kamimori, and
C Galinski, and
H Sing, and
M Thomas, and
G Belenky
January 2002,
Psychopharmacology,
D Penetar, and
U McCann, and
D Thorne, and
G Kamimori, and
C Galinski, and
H Sing, and
M Thomas, and
G Belenky
April 1994,
Behavioural pharmacology,
D Penetar, and
U McCann, and
D Thorne, and
G Kamimori, and
C Galinski, and
H Sing, and
M Thomas, and
G Belenky
December 2006,
Journal of sleep research,
D Penetar, and
U McCann, and
D Thorne, and
G Kamimori, and
C Galinski, and
H Sing, and
M Thomas, and
G Belenky
September 1996,
Aviation, space, and environmental medicine,
D Penetar, and
U McCann, and
D Thorne, and
G Kamimori, and
C Galinski, and
H Sing, and
M Thomas, and
G Belenky
January 1990,
Psychopharmacology,
D Penetar, and
U McCann, and
D Thorne, and
G Kamimori, and
C Galinski, and
H Sing, and
M Thomas, and
G Belenky
January 2006,
Current pharmaceutical design,
D Penetar, and
U McCann, and
D Thorne, and
G Kamimori, and
C Galinski, and
H Sing, and
M Thomas, and
G Belenky
October 1965,
The Journal of pharmacology and experimental therapeutics,
D Penetar, and
U McCann, and
D Thorne, and
G Kamimori, and
C Galinski, and
H Sing, and
M Thomas, and
G Belenky
September 1998,
Sleep,
